Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy

madman

Super Moderator

(UroToday.com) On the first day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023 focussing on prostate cancer, Dr. Wee Loon Ong presented in Poster Session A the results of an individual patient data meta-analysis from the MARCAP consortium aimed at assessing testosterone recovering following androgen suppression (androgen deprivation therapy; ADT) and prostate radiotherapy.


ADT of various durations has become the standard of care for many patients receiving primary radiation therapy for prostate cancer. The kinetics of testosterone recovery (TR) following this androgen suppression may vary widely between patients and has important implications for the patient’s quality of life. In this analysis, the authors sought to identify factors affecting the time to TR following ADT use.

To do so, they included trials of prostate radiotherapy and ADT in the Meta-Analysis of Randomized trials in the Cancer of the Prostate (MARCAP) consortium for which prospectively collected serial testosterone data was available. They examined the time to non-hypogonadal TR (NHTR) (>8.0nmol/L) and time to full TR (FTR) (>10.5nmol/L) from the date of first available testosterone at trial enrolment to the date of TR using the Kaplan-Meier method. Further, they assessed the effect of interactions between the duration of ADT and patients’ age on TR was evaluated.

They identified 1439 men with non-castrate testosterone at baseline (>1.7nmol/L) who met the inclusion criteria for analysis. Among these 1439 men, 220, 765 and 454 men had 3-, 6-, and 18 months of ADT.

As of the last follow-up, 959 (67%) men had FTR. For men who had 3-, 6-, and 18 months of ADT, the median time (range) to NHTR were 5.5 (1.6-76.3), 12.2 (0.8-53.6), and 30.1 (2.8-90.4) months respectively, while the median time (range) to FTR was 6.2 (1.8-75.7), 15.2 (0.8-86.0), and 36.0 (18.1-85.5) months respectively.


Screenshot (20840).webp


Among a subset of 1160 men who had normal testosterone at baseline (>10.5nmol/L), 851 (69%) men had FTR, with a median time (range) to FTR of 5.5 (1.8-75.7), 12.7 (1.8-86.0), and 30.8 (18.1-84.1) months for men who had 3-, 6- and 18-months ADT, respectively.

For any given duration of ADT, men aged above 65 years were less likely to have FTR compared to those aged under 65 years – HR=0.67 (95%CI=0.46-0.99), HR=0.80 (95%CI=0.67-0.96), HR=0.64 (95%CI=0.51-0.81) for men who had 3-, 6-, and 18-months ADT respectively. However, the authors found no evidence of interaction between the effect of ADT duration on time to FTR and age (interaction P=0.3 for the entire cohort).

They, therefore, concluded that in this the largest pooled analysis of prospectively collected serial testosterone data from randomized trials, a substantial delay in FTR in men receiving longer durations of ADT is common. Approximately one-third of the men did not achieve FTR, which may have a life-long impact on quality of life.
 

hCG Mixing Calculator

HCG Mixing Protocol Calculator

TRT Hormone Predictor Widget

TRT Hormone Predictor

Predict estradiol, DHT, and free testosterone levels based on total testosterone

⚠️ Medical Disclaimer

This tool provides predictions based on statistical models and should NOT replace professional medical advice. Always consult with your healthcare provider before making any changes to your TRT protocol.

ℹ️ Input Parameters

Normal range: 300-1000 ng/dL

Predicted Hormone Levels

Enter your total testosterone value to see predictions

Results will appear here after calculation

Understanding Your Hormones

Estradiol (E2)

A form of estrogen produced from testosterone. Important for bone health, mood, and libido. Too high can cause side effects; too low can affect well-being.

DHT

Dihydrotestosterone is a potent androgen derived from testosterone. Affects hair growth, prostate health, and masculinization effects.

Free Testosterone

The biologically active form of testosterone not bound to proteins. Directly available for cellular uptake and biological effects.

Scientific Reference

Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, Mazer NA, Bhasin S. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64.

DOI: 10.1210/jc.2010-0102 | PMID: 20534765 | PMCID: PMC2913038

Beyond Testosterone Podcast

Online statistics

Members online
7
Guests online
460
Total visitors
467

Latest posts

Back
Top